TTI — Thiogenesis Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$30.56m
- CA$26.42m
- 38
- 11
- 57
- 27
Annual cashflow statement for Thiogenesis Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Net Income/Starting Line | 0.1 | -5.06 |
| Non-Cash Items | — | 0.516 |
| Other Non-Cash Items | ||
| Changes in Working Capital | — | 1.3 |
| Change in Accounts Receivable | ||
| Change in Prepaid Expenses | ||
| Change in Payable / Accrued Expenses | ||
| Cash from Operating Activities | 0.1 | -3.25 |
| Other Investing Cash Flow Items | — | 0 |
| Sale of Business | ||
| Cash from Investing Activities | — | 0 |
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | — | 4.12 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 0.1 | 0.88 |